Share Email Print
cover

Proceedings Paper

Near infrared photoimmunotherapy: a new type of immune theranostic technology for cancer
Author(s): Hisataka Kobayashi
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Near infrared photoimmunotherapy (NIR-PIT) is a recently developed cancer-targeted theranostic technology that produces a therapeutic immune response. Conventional immunotherapies, such as immune-activating cytokine therapy, checkpoint inhibition, engineered T cells (e.g. chimeric antigen receptor or CAR-T cells) and suppressor cell depletion do not directly destroy cancer cells, but rely exclusively on activating the immune system. NIR-PIT not only selectively destroys cancer cells but also activates anti-cancer immune reactions that kill cells that escape direct killing. NIR-PIT can be applied to a wide variety of cancers either as monotherapy or in combination with other immune therapies to further activate anti-cancer immunity. The first NIR-PIT Phase 3 clinical trial targeting EGFR uses the antibody-photoabsorber conjugate (APC), cetuximab-IR700 (RM1929/ASP1929) and is now underway for recurrent and advanced head and neck cancer in North America, Asia and Europe (https://clinicaltrials.gov/ct2/show/NCT03769506). NIR-PIT has been given fast track status by regulators in the US and Japan. A variety of imaging methods can be used to monitor NIR-PIT therapy including optical methods such as direct IR700 fluorescence imaging before and during therapy with fluorescent endoscopy systems or a special camera using the therapeutic light as excitation. Other optical, PET and MR methods may be useful as well. NIR-PIT is a versatile method of treating cancers and will likely acquire specific roles for treating various cancers particularly those presenting with localized or locally advanced disease even with distant metastasis.

Paper Details

Date Published: 1 April 2020
PDF: 5 pages
Proc. SPIE 11362, Clinical Biophotonics, 113620S (1 April 2020); doi: 10.1117/12.2554486
Show Author Affiliations
Hisataka Kobayashi, NCI/NIH (United States)


Published in SPIE Proceedings Vol. 11362:
Clinical Biophotonics
Daniel S. Elson; Sylvain Gioux; Brian W. Pogue, Editor(s)

© SPIE. Terms of Use
Back to Top
PREMIUM CONTENT
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?
close_icon_gray